NIH ACTIV vaccine working group weighs role of human challenge studies for SARS-CoV-2 vaccine development
National Institutes of Health (NIH) sent this bulletin at 07/01/2020 05:30 PM EDTHaving trouble viewing this email? View it as a Web page.
You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
07/01/2020 05:00 PM EDT
The authors conclude that large, randomized, controlled trials of SARS-CoV-2 are the fastest and most effective path forward for establishing vaccine safety and efficacy.